key: cord-0253191-wy5z5oh1 authors: Qubais, B.; Al-Shahrabi, R.; Alhaj, S. S.; Alkokhardi, Z. M.; Adrees, A. O. title: Side Effects and Perceptions Following Sinopharm COVID-19 Vaccination date: 2021-07-01 journal: nan DOI: 10.1101/2021.06.28.21258847 sha: 9e506ae12a0de8278d378c94d57244b53d62852f doc_id: 253191 cord_uid: wy5z5oh1 Objectives Vaccines are one of the best interventions developed for eradicating COVID-19 the rapid creation of vaccinations was increased the risk of vaccine safety problems. The aim of this study to provide evidence on Sinopharm COVID-19 vaccine side effects. Methods A cross-sectional survey study was conducted between January and April 2021 to collect data on the effects of COVID-19 vaccine among individuals in the UAE. Demographic data chronic conditions side effects of the 1st and 2nd dose toward the vaccination, and the response of unwilling taking COVID-19 vaccine were reported. Results The most common side effects of post 1st dose (less than 49 years old vs >49 years) were normal injection site pain, fatigue, and headache while pain at the vaccination site fatigue lethargy headache and tenderness were the most side effects of the post 2nd dose in both groups. All the side effects in both doses were more prevalent among the participants less than 49-year-old group. Among females vs males side effects were more common in females compared with males in both doses in both doses. The most common adverse reactions of 1st dose in (females vs males) were fatigue lethargy headache while in 2nd dose were fatigue sever injection site pain. The most common reason of not willing to take the COVID-19 vaccine were the vaccines are not effective and they were not authorized to take vaccine. Conclusion The 1st and 2nd dose post-vaccination side effects were mild predictable and there were no hospitalization cases this data will help to reduce the vaccine hesitancy. The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) [1] . The virus has spread fast over the world, resulting various levels of illnesses. On March 11, 2020 , was announced that SARS-CoV-2 is a worldwide pandemic that has lasted through this moment [2] . Even though numerous therapeutic medications have been presented to resist COVID-19, they remain supportive and still require more randomized control studies to determine their efficacy and potency. [3, 4] . develop the vaccines is perhaps the best way to stopping this pandemic. Vaccines are one of the best interventions developed for eradicating COVID-19, it saving millions lives annually, moreover, the best option remains an effective, safe vaccine, and without serious adverse reactions. The lack of effective and approved treatment of COVID-19 has triggered a vaccine development race, with 259 COVID-19 vaccine projects underway from November 11, 2020. The rapid creation of vaccinations was increased the risk of vaccine safety problems [5, 6] . Several candidate COVID-19 vaccines were developed from diverse platforms, one of them BBIBP-CorV vaccine (also known as the Sinopharm COVID-19 vaccine) that was made by Chinese state-owned pharmaceutical business called Sinopharm in China that adopted by the UAE [7] . Sinopharm COVID-19 vaccine is an inactivated vaccine that introduces a dead copy of SARS-CoV-2 into the body by a two-dose schedule, with 14 or 21 days between the 2 doses. However, by inserting the vaccine dose intramuscularly, the dead antigens from the virus are employed to make antibodies that prepare the immune system for future attacks by the virus. [8] . The traditional inactivated whole-virus vaccines don't lead to a clinical disease. In this technology the inactivated viruses maintain their ability to replicate in vivo with mild or no symptoms. [9] . Clinical trial 1 and 2 of Sinopharm COVID-19 vaccine were done in China over 1 trial for each, with a total enrolment of 640 persons showed that the vaccine triggered a COVID-19 neutralizing antibody response with a low rate of adverse reactions. The most common side effects were fever and pain at the site of injection and fever, but were mild, self-limiting, and didn't required treatment [10] . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) instructions on how to complete the survey. Informed consent form that included statements about voluntary participation and anonymity was sought from all the respondents prior to data collection by sending a standardized general invitation letter with the survey link to accept or decline to participate in the study. The participant who declined consent were not permitted to open the survey and participate in the study, and participants could withdraw from the survey at any time in line with stipulations of the World Medical Association Declaration of Helsinki Ethical principles [18] . The members who clicked on the link were directed to the Google forms and to avoid the missing data, the participants were requested to fill all the questions of the survey or else could not proceed to the next section. No incentives or compensations have been given to participants. The total number of respondents was calculated. Out of 1102 survey received from respondents, 1080 participants were included in this study aged 18 years and above from different emirates and nationalities. The study sample included the participants who are either vaccinated with the first dose or the second dose of Sinopharm COVID-19 vaccine. Other participants were didn't get any COVID-19 vaccine during the early peak of the vaccination campaign in UAE. The study was approved by the Research Ethics Committee of university of Sharjah in the on: 22/3/2021, with the reference No: REC-21-02-09-07. The Survey was designed based on previous extensive literature search studies, and guidelines of WHO, MOHAP, DOH in UAE on the expected Adverse reactions post Sinopharm COVID-19 vaccine. the questions of survey were multiple choice, the survey was created in English and Arabic languages. [8, 15, 19] , it was validated by a group of experts who provided feedback on the different items of the survey. The survey were included three sections, the first section included 7 demographic questions such as (gender, age, marital status, education level, employment, nationality, and, the emirate of living) second section reviewed participant's chronic conditions such as (acute cancer, autoimmune diseases, chronic respiratory diseases, diabetes, hypertension, obesity, heart disease, severe allergic reactions to vaccination, receiving immunotherapy or inhibitor therapy, severe anemia, liver diseases, and no chronic condition). The last section was related to Sinopharm COVID-19 vaccine side effects, in the first order participant has been asked about his/her COVID-19 vaccination status to determine the scope of the rest of the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 1, 2021. ; https://doi.org/10.1101/2021.06.28.21258847 doi: medRxiv preprint questions, however, if the participant received the vaccine questions were as following (number of doses administered and the previous infection to COVID -19) , then questions regarding vaccine 1st and 2nd dose side effects were asked separately based on each dose side effects, mentioning : (normal/severe pain at the vaccination site, tenderness, redness, pruritus at the vaccination site, fever, headache, fatigue, nausea, diarrhea, cough, allergy, muscle pain, abdominal pain, back pain, lethargy). If the participant did not receive the any COVID-19 vaccine, a question to clarify the reasons behind the participant's hesitancy takes place. For pilot testing, a questionnaire was passed randomly to 15 participants recently vaccinated and filled the questionnaire after taking the two doses and have been excluded from the study. The Cronbach's alpha test of internal consistency was used to evaluate survey reliability. The overall reliability was equal to 0.81, which indicates that the survey tool was reliable with good internal consistency [20] . In our study the mean age was 37.2±13.1, given the fact that age has been classified into four groups ranged from the minimum of 18 to the maximum of 80 years old, the participants of 49 years old selected to be a cutting point to evaluate the differences of participants side effects between two groups (≤49 vs >49) using a chi-squared test. Similarly, chi-squared test was performed to assess the correlation between the presence of vaccine side effects and gender tolerability. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 1, 2021. ; Table 1 . shows the demographic data of participants, 760 (70.4%) were females, 320 (29.6%) were males. the mean age of participants was 37.22±13.1 years old. Of the participants, 440 (40.7%) were single, 600 (55.6%) were married and 3.7% were divorced or widower. About 644 (59.7%) were holding a bachelor's degree, 288 (21.1%) were holding a high school degree or below, and 180 (16.6%) were holding postgraduate degree. Around 508 (47.1%) were employed, 232 (21.5%) were unemployed and 304 (28.2%) were students. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 1, 2021. ; https://doi.org/10.1101/2021.06.28.21258847 doi: medRxiv preprint Of 1080 participants, 780 (72.2%) were healthy, while 300 (27.8%) had chronic conditions. The most prevalent chronic conditions as shown in table 2 were diabetes 7.8% followed by hypertension 6.3%, while 3.7%, 3.7%, 3.3%,0.7%, 0.7%, 0.4%, 0.4%, 0.4%, 0.4% suffer of chronic respiratory diseases, heart diseases, obesity, acute cancer, severe anemia, autoimmune diseases, severe allergic, receiving immunotherapy, and liver diseases, respectively. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 1, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 1, 2021. Relation between the side effects of vaccination with the gender (females and males) Table 6 shows the prevalence of side effects post 1 st dose of Sinopharm COVID-19 vaccination among two groups (females vs males). Our study was included 760 females and 320 males. The female's significance had more symptoms of 1 st vaccination than males (17% of females didn't have side effects vs 45% males didn't have side effects), however, significant relation reported between the symptoms such as fatigue (P=0.006) and gender. The results shows that no significant between the side effects of tenderness (P= 0.194), redness (p-value= 0.356), fever (P= 0.891) and headache (p-value= 0.434) with the gender. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 1, 2021. ; Table 7 presents the prevalence of side effects of 2nd dose of vaccination among females and males. The females had more side effect of 2 nd vaccination dose than males (11.6% of females didn't have side effects vs 20% males didn't have side effects), Sever pain at the vaccination site (P=0.027) and fatigue (P = 0.011) symptoms were significantly higher in females than males (10.5% vs 2.5%), (20% vs 7.5%), respectively. In addition, the table shows no significant between the symptoms of normal pain at vaccination site (P=0.482), tenderness (P= 0.368), redness (P = 0.834) fever (P = 0.279), and lethargy (P =0.053) with the genders. The most three common reasons reported by participants for not willing to take the vaccine were 6.3% not believing that the vaccine is effective, 5.2% pant wasn't authorized to take the vaccine and, 4.4% of them belief that the vaccine have many side effects, Moreover, the participants reported that "not have enough time" 3.7%, unavailability of the vaccine 3%, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 1, 2021. ; https://doi.org/10.1101/2021.06.28.21258847 doi: medRxiv preprint " the vaccines is not approved by WHO" 1.5%, being afraid of needles 1.1% and the least common reason was "waiting for another vaccine" 0.4% (table 8) . in August 2020, Trial 1 and 2 of Sinopharm vaccine were completed and showed that the vaccine triggered a COVID-19 neutralizing antibody response with a low rate of adverse reactions. The most common adverse reactions were pain at the site of injection and fever, but all these were mild and self-limiting, moreover, no treatment was required for any side effect [8] . UAE were among the first to conduct phase three clinical trials of the vaccine, they found that the vaccine to have an 86% efficacy rate according to interim results of its phase 3 trial [8] . Most of studies have assessed mainly the post-vaccination adverse reactions of the Pfizer-BioNTech, Moderna, and Astrazeneca vaccines [21, 22, 23, 24, 25] , while only two studies focus on Sinopharm COVID-19 vaccine [16, 17] , There are no published studies yet that have focused on Sinopharm COVID-19 vaccine side effects in UAE. The finding of our study shows that the side effects of this vaccines appear to be mild. Anecdotally, a quarter of participants reported they didn't get did not get any symptom in post-first vaccination shot, while had mild symptoms following vaccination. Second dose the 14% didn't report any symptoms, however, most of them had mild and predictable side effects. None of the side effects were of a serious nature or required hospitalization. Our results were in line of a study in India, as frequency of experiencing symptoms following each vaccine were 24.4% (Sinopharm). [16] . In first dose of vaccination the findings showed a statistically significant differences in the prevalence of severe pain at the vaccination site, nausea, and muscle pain, between the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 1, 2021. participants in both groups (≤49 vs >49). While in the 2nd dose showed a significant difference in the prevalence of Fatigue between two groups. Moreover, the more frequent side effect prevalence is normal Pain at the vaccination site (42.2%), fatigue (12.2%) headache (9.6%), lethargy (9.2%), and muscle pain (6.3%). The reported symptoms in our study were similar to symptoms that appear on participants in phase 1/2 trial of Sinopharm vaccine and reported by Sinopharm vaccine company, WHO, DOH and MOH in the UAE reported that the most adverse reactions were injection site reactions, headaches, fatigue, they indicated that the most common systematic adverse reaction was pain at the vaccination site fever, it was self-limited and recovered, none of the symptoms were of serious nature or requiring hospitalization. [8, 15, 19] Injection site pain symptom reported in several literatures on vaccines' side effects [16 Jayadevan, 17, 24, 25] , injection in a relaxed muscle leads to less pain compared to a tensed one; therefore, the researchers recommended to lower the patient's arm that will be injected to reduce the pain. In addition, vaccines in in situ should be keep it in a low temperature, including Sinopharm vaccine that should store at normal refrigeration temperature, and if injected without optimal warming up, this may increase the probability of pain of the injection site symptom. [ 17, 24, 26] . There was a clear linear correlation between age and vaccination side effects, the younger adults (≤49) were more frequently affected than other groups (>49). Vaccine reactogenicity is known to correlate with transient elevation of inflammatory cytokines, suggesting that the vaccine reactogenicity declined with age. but it is not considered a reliable sign of a desirable immune response [27] . Similar to our results showed in various studies on COVID-19 vaccine side effects [16, 24, 28] , Moreover, according to the Centers for Disease Control and Prevention (CDC), side effects tend to be more noticeable after the first dose [29]. Similar to findings of studies recently published [17, 25] We observed that the frequency of adverse effective in the second shot was slightly higher than to the first dose. Except some symptoms (1st vs 2nd), nausea (1.5% vs 1.1%), Allergy (1.1% vs 0), Cough (1.1% vs 0.7%), Abdominal Pain (1.85% vs 1.5%, Back pain (4.07% vs 3%), this finding could be interpreted on the basis response of the immune system's. The immune system could produce cytokines that could have an inflammatory effect on the blood vessels, muscles, and other tissues. It may also produce flu-like symptoms that last for days after vaccination. [7] . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 1, 2021. Women generally were more likely to develop side effects of vaccination than males, as 83% of the females reported they had side effects compared to 55% reported by males' participants post 1st dose of vaccination, while was (98.5% female vs, 80% males) for post 2nd dose of vaccination. Previous studies on COVID-19 vaccine have reported more side effect in females compared to males in both doses [16, 24, 25] . According to our results the (1.1%) of participants has been Allergic symptoms post -1st vaccination, while no cases for allergy reported among them post -2nd dose vaccination. This confirms that the participants with allergic reaction in this study did not receive the second dose of vaccination, there are no published data on the safety of the 2nd dose of covid vaccine after an allergic reaction to the first dose. one study indicated that anyone with immediate allergic reaction history of any severity to any component of mRNA COVID-19 vaccines or to polyethylene glycol or polysorbate should not be vaccinated with the Pfizer-BioNTech or Moderna COVID-19 vaccine. [30] . Allergic reactions to vaccines not attributed to the active vaccine itself, they might be caused by inactive ingredients, such as egg protein, gelatin, formaldehyde, thimerosal, or neomycin, that contribute to specific IgE-mediated immediate reactions. According to European Medicines Agency (EMA), Excipients, are constituents of a medicinal form apart from the active substance, it constitute inert substances that are added to vaccines to improve stability, increase solubility, improve absorption, influence palatability, or create a distinctive appearance. Excipients can cause various clinical allergic reactions ranging from skin disorders to life-threatening systemic reactions [31] . In our study, we noticed that the most prevalent chronic conditions among the UAE participants were diabetes 7.80%, and hypertension 6.30%, our results are consistent with the Dubai Statistical Center study that shows UAE nationals have a higher prevalence rate of diabetes and Hypertension diseases, furthermore, another study among patients with chronic disease in the UAE reported that 74.1% were Diabetics [32, 33] . Recent studies have shown that COVID-19 vaccine hesitancy level among residents varies from low to high, 29% of New York residents claiming they will refuse a vaccine, compared to 20% of Canadians residents, and 6% of among them in the United Kingdom. [34, 35] . In our study, a few percentages of the respondents reported that don't want to receive the COVID-19 vaccine, the most reasons of indecision and rejection about COVID-19 were . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 1, 2021. ; https://doi.org/10.1101/2021.06.28.21258847 doi: medRxiv preprint belief that the vaccine not effective, some of the participants were from the categories who are not authorized to take vaccine, while 4.4% were afraid of side effects of the vaccine. Several studies in the scientific literature reported the similar reasons, Thus, knowing what to expect post-vaccination from this study will help with public education, dispelling myths, and lowering the apprehension about Sinopharm COVID-19 vaccines. similar reasons reported in several studies, as the side effects of vaccine, don't think the vaccine can be reliable as it will be a new vaccine, and COVID-19 infection is a biological weapon and the vaccine will serve those who produce this virus, were the most common reasons for rejection of vaccine [36] Conclusion Fear of the unknown is a driver of vaccine hesitancy. This study showed that 1st and 2nd dose post-vaccination adverse reactions of Sinopharm COVID-19 vaccine were common side effects, mild, predictable, non-life-threatening, and none were serious. To our knowledge, this is the first design dealing with the Sinopharm vaccine side and evaluating the side effects among a UAE population, the results may help reduce vaccine hesitancy of the public. Resolution of coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges Coronavirus disease (COVID-19): How is it transmitted Investigational treatments for COVID-19 COVID-19 Vaccine: Critical Questions with Complicated Answers Correction to: Assessing the Safety of COVID-19 Vaccines: A Primer Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized clinical trials COVID-19 Commission of Accademia Nazionale deiLincei, Rome. COVID-19 vaccines: Where we stand and challenges ahead A Review of the Progress and Challenges of Developing a Vaccine for COVID-19 China to run human coronavirus vaccine trial in UAE. Reuters Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 Arab nations first to approve Chinese COVID vaccine -despite lack of public data A review on COVID-19 vaccines: stages of clinical trials, mode of actions and efficacy Evidence Assessment: Sinopharm/BBIBP COVID-19 vaccine, for recommendation by the strategic advisory group of experts (sage) on immunization prepared by the sage working group on covid-19 vaccines Survey of symptoms following COVID-19 vaccination in India Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects COVID-19 Vaccine Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed selfreported symptoms from healthcare workers Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. 2021 Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Stud China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says The how's and what's of vaccine reactogenicity Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine Ming-Yow Hung M. Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations. Vaccines Delayed Hypersensitivity Reactions Caused by Drug Excipients: A Literature Review Barriers affecting compliance of patients with chronic diseases: A preliminary study in United Arab Emirates (UAE) population About 20% of people in recent survey said they wouldn't take COVID-19 vaccine Coronavirus causing some anti-vaxxers to waver, experts say While studies on COVID-19 vaccine is ongoing, the public's thoughts and attitudes to the future COVID-19 vaccine